Comparative Pharmacology
Head-to-head clinical analysis: AMONDYS 45 versus SPINRAZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMONDYS 45 versus SPINRAZA.
AMONDYS 45 vs SPINRAZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amondys 45 (casimersen) is a phosphorodiamidate morpholino oligomer that binds to exon 45 of dystrophin pre-mRNA, excluding it during splicing to restore the mRNA reading frame in Duchenne muscular dystrophy (DMD) patients with amenable mutations. This enables production of internally truncated but functional dystrophin protein.
SPINRAZA (nusinersen) is an antisense oligonucleotide that modifies splicing of pre-messenger RNA of the survival motor neuron 2 (SMN2) gene to increase production of full-length SMN protein, which is deficient in spinal muscular atrophy (SMA).
Intravenous infusion over 35-60 minutes: 30 mg/kg once every 7 days.
Loading dose: 12 mg (5 mL) intrathecally on days 0, 14, 28, and 63. Maintenance dose: 12 mg (5 mL) intrathecally once every 4 months.
None Documented
None Documented
Terminal elimination half-life is approximately 3.6 hours, necessitating frequent dosing (weekly) to maintain therapeutic levels.
Terminal elimination half-life in cerebrospinal fluid (CSF) is 135–177 days; in plasma, it is 63–87 days. The long CSF half-life supports monthly intrathecal dosing.
Primarily renal, with 100% of the dose excreted as unchanged drug in urine.
Primarily metabolized via exonuclease-mediated hydrolysis; renal excretion of intact drug is negligible (<1%). No biliary or fecal elimination is documented.
Category C
Category C
Antisense Oligonucleotide
Antisense Oligonucleotide